SCHEMBL13435164

SCHEMBL13435164

CCOC(=O)C1(Cc2ccccc2)CCC(NC2C3CC4CC(C3)CC2C4)CC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
KDM4E B2RXH2 2/20 0.48
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
CXCR3 P49682 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 3/20 0.44
HTT P42858 1/20 0.43
EPHX2 P34913 1/20 0.43
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13435166 0.86 CXCR3 (0.54) KMT2AMEN1CXCR3EPHX2
SCHEMBL3718479 0.75 KDM4E (0.64) LMNAKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL6627628 0.75 KDM4E (0.64) LMNAKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL14074899 0.74 KDM4E (0.62) LMNAKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL13435159 0.71 LMNA (0.59) LMNAKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL962133 0.71 OPRM1 (0.62) LMNAKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL8283153 0.71 LMNA (0.59) LMNAKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL16864106 0.70 LMNA (0.72) LMNAKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL12946592 0.70 SMN1; SMN2 (0.71) LMNAKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL13435155 0.70 ALOX15 (0.52) KMT2ACXCR3EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687644-B2 Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2010-03-30 US disclosed
US-7687644-B2 Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2010-03-30 US disclosed
US-20070287743-A1 Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-13 US disclosed
US-20070287743-A1 Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287743-A1 Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors HSD11B1, HSD11B2, HSDL2 LMNA 1720/4885KDM4E 4172/4885KMT2A 3591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.